Department of Pediatrics, Stanford University Medical School, Stanford University, Stanford, CA 94305, USA.
Expert Rev Proteomics. 2011 Dec;8(6):705-15. doi: 10.1586/epr.11.66.
The identification and clinical use of more sensitive and specific biomarkers in the field of solid organ transplantation is an urgent need in medicine. Solid organ transplantation has seen improvements in the short-term survival of transplanted organs due to recent advancements in immunosuppressive therapy. However, the currently available methods of allograft monitoring are not optimal. Recent advancements in assaying methods for biomolecules such as genes, mRNA and proteins have helped to identify surrogate biomarkers that can be used to monitor the transplanted organ. These high-throughput 'omic' methods can help researchers to significantly speed up the identification and the validation steps, which are crucial factors for biomarker discovery efforts. Still, the progress towards identifying more sensitive and specific biomarkers remains a great deal slower than expected. In this article, we have evaluated the current status of biomarker discovery using proteomics tools in different solid organ transplants in recent years. This article summarizes recent reports and current status, along with the hurdles in efficient biomarker discovery of protein biomarkers using proteomics approaches. Finally, we will touch upon personalized medicine as a future direction for better management of transplanted organs, and provide what we think could be a recipe for success in this field.
在实体器官移植领域中,鉴定和临床应用更敏感和更特异的生物标志物是医学领域的迫切需求。由于最近免疫抑制治疗的进展,实体器官移植使移植器官的短期存活率得到了提高。然而,目前同种异体移植监测的方法并不理想。近年来,生物分子(如基因、mRNA 和蛋白质)检测方法的进步有助于鉴定可用于监测移植器官的替代生物标志物。这些高通量的“组学”方法可以帮助研究人员大大加快鉴定和验证步骤,这是生物标志物发现工作的关键因素。尽管如此,鉴定更敏感和更特异的生物标志物的进展仍然比预期的要慢得多。在本文中,我们评估了近年来不同实体器官移植中使用蛋白质组学工具进行生物标志物发现的现状。本文总结了最近的报告和现状,以及使用蛋白质组学方法发现蛋白质生物标志物的有效生物标志物所面临的障碍。最后,我们将探讨个性化医疗作为更好地管理移植器官的未来方向,并提供我们认为在该领域取得成功的方法。